Inherited Platelet Function Disorders
USMLE Step 1 trap: Confuses the specific glycoprotein defect in Bernard-Soulier vs Glanzmann thrombasthenia. Bernard-Soulier lacks GPIb (adhesion defect, no vWF binding) while Glanzmann lacks GPIIb/IIIa (aggregation defect, no fibrinogen binding).
Inherited platelet function disorders are a high-yield, high-clarity topic on USMLE Step 1 — the exam essentially reduces this to one comparison: Bernard-Soulier syndrome versus Glanzmann thrombasthenia. Both cause mucocutaneous bleeding with a prolonged bleeding time and normal PT/PTT/platelet count, but they differ in mechanism, platelet size, and aggregation pattern. The most common wrong assumption: that Bernard-Soulier fails all aggregation agonists. It doesn't — only ristocetin fails, because GPIb (the absent receptor) mediates vWF-dependent adhesion, not aggregation. All other agonists work normally in Bernard-Soulier. It's Glanzmann thrombasthenia (GPIIb/IIIa absent) where all aggregation agonists fail but ristocetin is spared. That reversal is exactly what the exam tests.
The way USMLE Step 1 tests this is almost always differential-style: a clinical vignette describes a patient with bleeding symptoms and abnormal lab results, then asks you to identify the defect or explain why a specific aggregation study is abnormal. The tricky part isn't memorizing the names — it's knowing which glycoprotein does what and how that maps onto the ristocetin aggregation test. Students who just memorize 'GPIb = Bernard-Soulier' without understanding that GPIb mediates vWF-dependent adhesion (not aggregation) will get burned on a question asking why ristocetin specifically fails.
The three misconceptions that consistently trip students up are: (1) confusing which glycoprotein is defective in each disorder, (2) misapplying the ristocetin aggregation result — particularly assuming Bernard-Soulier fails all agonists when it only fails ristocetin — and (3) forgetting that Bernard-Soulier shows giant platelets on peripheral smear while Glanzmann does not. Platelet size on smear is a classic exam discriminator that students miss because they focus on aggregation and ignore morphology.
Common misconceptions
Stuck on this? An AI tutor that probes your understanding and catches where your reasoning breaks.
Start a session →What the exam tests
- Given a patient's clinical presentation, lab results (bleeding time, platelet count, PT/PTT), and platelet aggregation study results, correctly identify whether the defect is Bernard-Soulier (GPIb deficiency) or Glanzmann thrombasthenia (GPIIb/IIIa deficiency) — and explain the mechanism behind the abnormal result.
Can you avoid these mistakes?
Related topics
Find out what you actually understand about this topic — a tutor that probes your reasoning and catches where it breaks.
Start a session →Already run Anki? Get a free deck audit →